Seeking Alpha

Anacor Pharmaceuticals (ANAC +26.5%) soars today after the company said earlier that Phase 2...

Anacor Pharmaceuticals (ANAC +26.5%) soars today after the company said earlier that Phase 2 study results showed its AN2728 ointment reduced skin lesions in adolescents with atopic dermatitis, with 57 of the 86 patients between the ages of 12 to 17 years old showing complete or partial improvement compared to a standard baseline.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|